Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan Plus Bevacizumab vs LONSURF Plus Bevacizumab in Refractory Metastatic Colorectal Cancer
NCT07525206Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 10
01
Overview
A Phase 3 trial of telisotuzumab adizutecan in colorectal cancer (CRC), sponsored by AbbVie Inc.. Started May 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07525206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07525206.